Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery June 10, 2019 - NASDAQ Companies 0 » View More News for June 10, 2019